adri67 schreef op 22 januari 2018 17:43:
AXSM= Market Cap $75 M / $41 Million or untill end 2019 / 6x Phase 3 Programs in different Indications . Shares Outstanding 25.4 Million more than 16 Millione of these shares held by Insiders and Institutions alone Ceo is largest shareholder with over 7.3 million Shares . Very experienced Management who brought many Products to market . AXSM is definitely one of the most attractive and massive undervalued Biotech you can get at this time .Dont let trolls mislead you always do your own dd thanks and good luck to all . More infos below
Latest Presentation :
media.corporate-ir.net/media_files/IR...Mega Pipeline of 6 Phase 3 Programs :
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.
AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.
AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.
AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.
AXS-06(MoSEIC™ Mx + Eso) Acute and Chronic Pain Phase 3 Ready = 120M NSAID TRx per year in the U.S.
AXS-07 (meloxicam and rizatriptan) for the Treatment of Migraine Phase 3 Ready = Migraine attacks are disabling and affect more than 37 million Americans
MAJOR SHAREHOLDERS :
Herriott Tabuteau, MD 7 351 729 31,1%
Fidelity Management & Research Co. 1 516 212 6,42%
JPMorgan Asset Management (UK) Ltd. 1 432 456 6,07%
Sabby Capital LLC 1 408 000 5,96%
Laurence W. Lytton 1 300 692 5,51%
Royce & Associates LP 881 000 3,73%
Mark Coleman, MD 647 998 2,75%
Sphera Funds Management Ltd. 501 000 2,12%
The Vanguard Group, Inc. 418 022 1,77%
Stifel Trust Co., NA 415 279 1,76%
thx to Bernstein